JP2022517189A5 - - Google Patents
Info
- Publication number
- JP2022517189A5 JP2022517189A5 JP2021539020A JP2021539020A JP2022517189A5 JP 2022517189 A5 JP2022517189 A5 JP 2022517189A5 JP 2021539020 A JP2021539020 A JP 2021539020A JP 2021539020 A JP2021539020 A JP 2021539020A JP 2022517189 A5 JP2022517189 A5 JP 2022517189A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- oxo
- isopropyl
- pyrimidine
- dihydropyrido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/070275 | 2019-01-03 | ||
| CN2019070275 | 2019-01-03 | ||
| CN2019081673 | 2019-04-08 | ||
| CNPCT/CN2019/081673 | 2019-04-08 | ||
| PCT/US2020/012058 WO2020142612A1 (en) | 2019-01-03 | 2020-01-02 | Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517189A JP2022517189A (ja) | 2022-03-07 |
| JP2022517189A5 true JP2022517189A5 (cg-RX-API-DMAC7.html) | 2023-01-04 |
| JP7539892B2 JP7539892B2 (ja) | 2024-08-26 |
Family
ID=69400641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539020A Active JP7539892B2 (ja) | 2019-01-03 | 2020-01-02 | 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素i(ireiアルファ)の阻害剤としてのピリド-ピリミジノン化合物及びプテリジノン化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12344603B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3941919B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7539892B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113508115A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI748317B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020142612A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI831829B (zh) | 2018-09-12 | 2024-02-11 | 美商建南德克公司 | 苯氧基-吡啶基-嘧啶化合物及使用方法 |
| WO2020142612A1 (en) | 2019-01-03 | 2020-07-09 | Genentech, Inc. | Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases. |
| TWI756636B (zh) * | 2019-02-18 | 2022-03-01 | 美商建南德克公司 | 嘧啶并嘧啶化合物及使用方法 |
| SI4073065T1 (sl) | 2019-12-10 | 2025-06-30 | F. Hoffmann-La Roche Ag | Novi derivati metilkinazolinona |
| PE20231311A1 (es) | 2020-11-18 | 2023-08-24 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos |
| WO2022129259A1 (en) | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | New quinazolinone derivatives |
| CN118561841A (zh) * | 2020-12-18 | 2024-08-30 | 豪夫迈·罗氏有限公司 | 新的芳基-吡啶并-嘧啶-酮衍生物 |
| AU2022290851A1 (en) | 2021-06-08 | 2023-11-23 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| CN115850281A (zh) * | 2021-09-24 | 2023-03-28 | 华东理工大学 | 蝶啶酮衍生物及其应用 |
| MX2024006627A (es) | 2021-12-03 | 2024-08-22 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos. |
| CN119343346A (zh) * | 2022-06-08 | 2025-01-21 | 韩国化学研究院 | 苯磺酰胺衍生物、其制备方法及含有其作为活性成分的预防或治疗癌症的药物组合物 |
| WO2024131893A1 (en) * | 2022-12-22 | 2024-06-27 | Shanghai Yi Zhong Xing Biotechnology Co., Ltd. | IRE1α SMALL MOLECULE INHIBITORS |
| US12573866B2 (en) | 2023-11-17 | 2026-03-10 | Exro Technologies Inc. | Battery system for operating point control of power systems |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JP2003509425A (ja) * | 1999-09-15 | 2003-03-11 | ワーナー−ランバート・カンパニー | キナーゼ阻害剤としてのプテリジノン |
| KR100571339B1 (ko) * | 2000-08-31 | 2006-04-17 | 에프. 호프만-라 로슈 아게 | 세포증식 억제제로서의 7-옥소 피리도피리미딘 |
| WO2004063195A1 (en) * | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Pyridopyrimidine kinase inhibitors |
| WO2005034869A2 (en) * | 2003-10-08 | 2005-04-21 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| EP1751136B1 (en) | 2004-05-07 | 2014-07-02 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| WO2006002367A1 (en) * | 2004-06-23 | 2006-01-05 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| EP1831215A1 (en) * | 2004-11-23 | 2007-09-12 | Ranbaxy Laboratories Limited | Pyrido[2,3-d]pyrimidines as anti-inflamatory agents |
| WO2006082492A1 (en) * | 2005-02-02 | 2006-08-10 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as anti-inflammatory agents |
| US7868177B2 (en) | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| JP2009537520A (ja) * | 2006-05-15 | 2009-10-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Fgf受容体キナーゼ阻害剤のための組成物および方法 |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| WO2008055842A1 (en) | 2006-11-09 | 2008-05-15 | F. Hoffmann-La Roche Ag | Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same |
| EP2094682A2 (en) | 2006-12-22 | 2009-09-02 | Novartis AG | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| CN104230901A (zh) | 2008-09-15 | 2014-12-24 | 加利福尼亚大学董事会 | 用于调节ire1、src和abl活性的方法和组合物 |
| WO2011097526A1 (en) * | 2010-02-05 | 2011-08-11 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| BR112014010631A2 (pt) * | 2011-11-04 | 2017-04-25 | Afraxis Holdings Inc | inibidores de pak para o tratamento da síndrome do x frágil |
| WO2013090840A1 (en) | 2011-12-15 | 2013-06-20 | Gilead Sciences, Inc. | 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors |
| CA2886240A1 (en) | 2012-09-26 | 2014-04-03 | The Regents Of The University Of California | Modulation of ire1 |
| WO2014179498A1 (en) * | 2013-04-30 | 2014-11-06 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| US20140323478A1 (en) * | 2013-04-30 | 2014-10-30 | Afraxis Holdings, Inc. | Serine/threonine kinase inhibitors |
| WO2014182829A1 (en) * | 2013-05-09 | 2014-11-13 | Principia Biopharma Inc. | Quinolone derivatives as fibroblast growth factor inhibitors |
| WO2018102751A1 (en) | 2016-12-02 | 2018-06-07 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| TW201838981A (zh) | 2017-03-17 | 2018-11-01 | 美商建南德克公司 | 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法 |
| AU2018278311B2 (en) | 2017-06-01 | 2021-10-07 | Cornell University | IRE1 small molecule inhibitors |
| US10392367B2 (en) | 2017-06-01 | 2019-08-27 | Quentis Therapeutics, Inc. | IRE1 small molecule inhibitors |
| WO2018222917A1 (en) | 2017-06-01 | 2018-12-06 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| TWI831829B (zh) | 2018-09-12 | 2024-02-11 | 美商建南德克公司 | 苯氧基-吡啶基-嘧啶化合物及使用方法 |
| JP7546299B2 (ja) | 2018-12-03 | 2024-09-06 | コーネル・ユニバーシティー | Ire1小分子阻害物質 |
| WO2020142612A1 (en) | 2019-01-03 | 2020-07-09 | Genentech, Inc. | Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases. |
| CN114072148A (zh) | 2019-05-03 | 2022-02-18 | 金耐特生物制药公司 | Raf激酶的抑制剂 |
| KR102396930B1 (ko) | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
-
2020
- 2020-01-02 WO PCT/US2020/012058 patent/WO2020142612A1/en not_active Ceased
- 2020-01-02 TW TW109100113A patent/TWI748317B/zh active
- 2020-01-02 EP EP20702937.2A patent/EP3941919B1/en active Active
- 2020-01-02 JP JP2021539020A patent/JP7539892B2/ja active Active
- 2020-01-02 CN CN202080017509.0A patent/CN113508115A/zh active Pending
-
2021
- 2021-07-02 US US17/366,923 patent/US12344603B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6754864B2 (ja) | Egfr変異型キナーゼ活性をモジュレートするための化合物および組成物 | |
| JP2026009899A (ja) | NaV1.8を阻害するピリジンカルボキサミド化合物 | |
| JP6736559B2 (ja) | トリアゾロピリミジン化合物およびその使用 | |
| JP2025508702A (ja) | キナゾリン化合物、及び変異krasタンパク質の阻害剤としてのその使用 | |
| JP2021524484A5 (cg-RX-API-DMAC7.html) | ||
| KR20260047565A (ko) | 통증에 대한 신규 치료 | |
| JP7539892B2 (ja) | 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素i(ireiアルファ)の阻害剤としてのピリド-ピリミジノン化合物及びプテリジノン化合物 | |
| KR20010050223A (ko) | Crf 길항제 및 관련 조성물의 용도 | |
| ES2798424T3 (es) | Compuestos de triazolopiridina y usos de estos | |
| JP7611154B2 (ja) | ピリド-ピリミジニル化合物及び使用の方法 | |
| JP7320600B2 (ja) | フェノキシ-ピリジル-ピリミジン化合物及び使用方法 | |
| JP2005538099A5 (cg-RX-API-DMAC7.html) | ||
| JP2011510995A5 (cg-RX-API-DMAC7.html) | ||
| JP2013056930A5 (cg-RX-API-DMAC7.html) | ||
| RU2009125916A (ru) | Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения | |
| JP7768880B2 (ja) | Ezh2を阻害するためのキノリン化合物および組成物 | |
| US20240245634A1 (en) | Pcna inhibitors and egfr inhibitors for cancer treatment | |
| JP2022539830A5 (cg-RX-API-DMAC7.html) | ||
| JP2022550353A (ja) | アザキノリン化合物およびその使用 | |
| KR20170129757A (ko) | Fgfr4 억제제로서의 포르밀화 n-헤테로시클릭 유도체 | |
| WO2020176501A1 (en) | Compounds useful for inhibiting raf dimers | |
| TWI691500B (zh) | 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物 | |
| RU2393157C1 (ru) | 2-АЛКИЛАМИНО-3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| HK40097521A (en) | Tricyclic compounds and uses thereof | |
| HK40080941A (en) | Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases |